gadolinium dtpa has been researched along with acetazolamide in 8 studies
| Studies (gadolinium dtpa) | Trials (gadolinium dtpa) | Recent Studies (post-2010) (gadolinium dtpa) | Studies (acetazolamide) | Trials (acetazolamide) | Recent Studies (post-2010) (acetazolamide) |
|---|---|---|---|---|---|
| 12,654 | 664 | 4,051 | 7,604 | 495 | 1,521 |
| Protein | Taxonomy | gadolinium dtpa (IC50) | acetazolamide (IC50) |
|---|---|---|---|
| Chain A, Class Iii Chitinase Chia1 | Aspergillus fumigatus A1163 | 164 | |
| Carbonic anhydrase 12 | Homo sapiens (human) | 0.3178 | |
| Renin | Homo sapiens (human) | 8.2 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 2.3173 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 1.2619 | |
| Carbonic anhydrase 2 | Bos taurus (cattle) | 0.7 | |
| Carbonic anhydrase 3 | Homo sapiens (human) | 1.95 | |
| Cathepsin B | Bos taurus (cattle) | 0.02 | |
| Steryl-sulfatase | Homo sapiens (human) | 0.025 | |
| Carbonic anhydrase 4 | Homo sapiens (human) | 0.1216 | |
| Carbonic anhydrase 6 | Homo sapiens (human) | 0.2925 | |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | 0.1763 | |
| Carbonic anhydrase 7 | Homo sapiens (human) | 1.1737 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 0.464 | |
| Renin | Macaca mulatta (Rhesus monkey) | 8.2 | |
| Carbonic anhydrase 13 | Homo sapiens (human) | 0.23 | |
| Carbonic anhydrase 4 | Bos taurus (cattle) | 0.07 | |
| Carbonic anhydrase 13 | Mus musculus (house mouse) | 0.77 | |
| Carbonic anhydrase 14 | Homo sapiens (human) | 0.183 | |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | 0.23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aicher, KP; Engelstad, BL; Kucharczyk, J; Moseley, ME; Tzika, AA; White, DL | 1 |
| Chang, C; Cheng, HM; Kwong, KK; Xiong, J | 1 |
| Brix, G; Georgi, M; Gückel, F; Köpke, J; Lämmler, B; Piepgras, A; Rempp, K; Schmiedek, P | 1 |
| Becker, G; Brix, G; Georgi, M; Gross, H; Gückel, FJ; Köpke, J; Piepgras, Z; Schmiedek, P | 1 |
| Adeleine, P; Berthezene, Y; Cinotti, L; Froment, JC; Meyer, R; Nighoghossian, N; Philippon, B; Trouillas, P | 1 |
| Adeleine, P; Berthezene, Y; Cinotti, L; Damien, J; Froment, JC; Meyer, R; Nighoghossian, N; Trouillas, P | 1 |
| Gillies, RJ; Howison, C; Raghunand, N; Sherry, AD; Zhang, S | 1 |
| Ishiyama, A; Ishiyama, G; Sepahdari, AR; Vorasubin, N | 1 |
8 other study(ies) available for gadolinium dtpa and acetazolamide
| Article | Year |
|---|---|
Iron-dextran as a magnetic susceptibility contrast agent: flow-related contrast effects in the T2-weighted spin-echo MRI of normal rat and cat brain.
Topics: Acetazolamide; Animals; Brain; Capillaries; Cats; Cerebrovascular Circulation; Contrast Media; Dextrans; Electron Spin Resonance Spectroscopy; Ferrosoferric Oxide; Gadolinium; Gadolinium DTPA; Image Enhancement; Iron; Iron-Dextran Complex; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Meglumine; Organometallic Compounds; Oxides; Pentetic Acid; Rats; Rats, Inbred Strains; Rheology | 1992 |
GdDTPA-enhanced magnetic resonance imaging of the aqueous flow in the rabbit eye.
Topics: Acetazolamide; Animals; Anterior Chamber; Aqueous Humor; Ciliary Body; Contrast Media; Cornea; Gadolinium; Gadolinium DTPA; Injections, Intravenous; Iris; Magnetic Resonance Imaging; Ophthalmic Solutions; Organometallic Compounds; Pentetic Acid; Rabbits; Time Factors | 1991 |
[Noninvasive quantification of cerebral blood volume and blood flow with dynamic MR tomography. Studies of probands and patients with cerebrovascular insufficiency].
Topics: Acetazolamide; Blood Flow Velocity; Blood Volume; Brain; Cerebral Cortex; Cerebrovascular Disorders; Contrast Media; Dominance, Cerebral; Gadolinium DTPA; Humans; Magnetic Resonance Angiography; Organometallic Compounds; Pentetic Acid; Reference Values; Regional Blood Flow | 1995 |
Cerebrovascular reserve capacity in patients with occlusive cerebrovascular disease: assessment with dynamic susceptibility contrast-enhanced MR imaging and the acetazolamide stimulation test.
Topics: Acetazolamide; Adult; Aged; Blood Volume; Cerebrovascular Circulation; Contrast Media; Drug Combinations; Female; Gadolinium DTPA; Humans; Ischemic Attack, Transient; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Organometallic Compounds; Pentetic Acid | 1996 |
Assessment of cerebrovascular reactivity by dynamic susceptibility contrast-enhanced MR imaging.
Topics: Acetazolamide; Adult; Aged; Anticonvulsants; Brain; Cardiovascular Diseases; Cerebrovascular Circulation; Contrast Media; Drug Combinations; Female; Gadolinium DTPA; Humans; Magnetic Resonance Angiography; Male; Meglumine; Middle Aged; Organometallic Compounds; Pentetic Acid; Vasodilator Agents | 1997 |
Can cerebrovascular reactivity be assessed by dynamic susceptibility contrast-enhanced MRI?
Topics: Acetazolamide; Adult; Aged; Blood Flow Velocity; Blood Volume; Brain; Carbonic Anhydrase Inhibitors; Contrast Media; Dominance, Cerebral; Female; Gadolinium DTPA; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Reference Values; Regional Blood Flow; Vasomotor System | 1998 |
Renal and systemic pH imaging by contrast-enhanced MRI.
Topics: Acetazolamide; Acidosis, Renal Tubular; Animals; Contrast Media; Female; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds, 1-Ring; Hydrogen-Ion Concentration; Kidney; Kidney Cortex; Kidney Medulla; Magnetic Resonance Imaging; Mice; Mice, Inbred C3H; Mice, SCID; Organometallic Compounds; Organophosphorus Compounds; Ureter | 2003 |
Endolymphatic Hydrops Reversal following Acetazolamide Therapy: Demonstration with Delayed Intravenous Contrast-Enhanced 3D-FLAIR MRI.
Topics: Acetazolamide; Adult; Contrast Media; Endolymphatic Hydrops; Female; Gadolinium DTPA; Humans; Image Enhancement; Imaging, Three-Dimensional; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Meniere Disease; Middle Aged; Organometallic Compounds; Treatment Outcome | 2016 |